1887

Chapter 41 : Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch41-1.gif /docserver/preview/fulltext/10.1128/9781555819071/9781555819088.ch41-2.gif

Abstract:

While access to care and treatment for HIV/AIDS in the developed world is good, in resource-limited settings there still is a need to increase basic access to diagnostics for early detection and treatment. The most persistent challenges in the developing world are molecular tests for early infant diagnosis (EID) and viral load testing for monitoring patients on antiretroviral therapy (ART). The majority of molecular testing options available globally are laboratory-based tests performed on sophisticated instruments requiring dedicated laboratory space and trained technicians. With respect to both viral load and EID testing, there are a good number of platforms available, but their cost and complexity are barriers in resource-limited settings. In the interest of improving the accessibility and affordability of high-quality ART, there is a growing demand for simple, affordable, reliable, and quality-assured point-of-care (POC) diagnostics for use in resource-limited settings. Many contend that POC diagnostics can make ART more scalable and will allow ART service delivery to be significantly decentralized to the community level. At the same time, simplifying diagnostic technologies may reduce the cost of diagnosing and monitoring HIV/AIDS patients without diminishing the quality of care.

Citation: Murtagh M. 2016. Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings, p 580-588. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch41
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

SAMBA amplification process showing lattice structures.

Citation: Murtagh M. 2016. Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings, p 580-588. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

BART heat elution sample preparation technology.

Citation: Murtagh M. 2016. Molecular Diagnostics for Use in HIV/AIDS Care and Treatment in Resource-Limited Settings, p 580-588. In Persing D, Tenover F, Hayden R, Ieven M, Miller M, Nolte F, Tang Y, van Belkum A (ed), Molecular Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555819071.ch41
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819071.ch41
1. World Health Organization. 2013. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. WHO, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf?ua=1.
2. Osmond DH. 1998. Epidemiology of disease progression in HIV. USCF HIV InSite. http://hivinsite.ucsf.edu/InSite?page=kb-00&doc=kb-03-01-04.
3. Dewhurst SL, da Cruz RL, Whetter L. 2000. Pathogenesis and treatment of HIV-1 infection: recent developments (Y2K update). Front Biosci 5:D30D49.[PubMed]
4. Pantaleo G, Graziosi C, Fauci AS. 1993. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 328:327335.[PubMed]
5. World Health Organization. 2010. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendation for a Public Health Approach; 2010 revision. WHO, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
6. World Health Organization. 2010. Technical Brief on CD4 Technologies. WHO, Geneva, Switzerland. http://www.who.int/hiv/topics/treatment/tech_brief_20100501_en.pdf.
7. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:11671170.[PubMed]
8. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J, AIDS Clinical Trials Group (ACTG) 116B/117 Study Team, ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. 1996. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 174:704712.
9. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD, VA Cooperative Study Group on AIDS. 1997. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 126:939945.
10. Constantine NT, Saville RD, Dax EM. 2005. Retroviral Testing and Quality Assurance Essentials for Laboratory Diagnosis. University of Maryland, Baltimore, MD.
11. Swanson P, de Mendoza C, Joshi Y, Golden A, Hodinka RL, Soriano V, Devare SG, Hackett J Jr. 2005. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J Clin Microbiol 43:38603868.[PubMed]
12. von Truchsess I, Harris B, Schätzl HM, Hackett J Jr. 2006. The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J Med Virol 78:311317.[PubMed]
13. Andreotti M, Pirillo M, Guidotti G, Ceffa S, Paturzo G, Germano P, Luhanga R, Chimwaza D, Mancini MG, Marazzi MC, Vella S, Palombi L, Giuliano M. 2010. Correlation between HIV-1 viral load quantification in plasma, dried blood spots, and dried plasma spots using the Roche COBAS Taqman assay. J Clin Virol 47:47.[PubMed]
14. Garrido C, Zahonero N, Corral A, Arredondo M, Soriano V, de Mendoza C. 2009. Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. J Clin Microbiol 47:10311036.[PubMed]
15. Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, Kasubi MJ, Gundersen SG, Bruun JN, de Mendoza C. 2009. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Clin Infect Dis 49:976981.[PubMed]
16. Marconi A, Balestrieri M, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, Pecorari M, Borghi V, Marri D, Zazzi M. 2009. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 15:9397.[PubMed]
17. Arredondo M, Garrido C, Parkin N, Zahonero N, Bertagnolio S, Soriano V, de Mendoza C. 2012. Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. J Clin Microbiol 50:569572.[PubMed]
18. Pirillo MF, Recordon-Pinson P, Andreotti M, Mancini MG, Amici R, Giuliano M. 2011. Quantification of HIV-RNA from dried blood spots using the Siemens VERSANT® HIV-1 RNA (kPCR) assay. J Antimicrob Chemother 66:28232826.[PubMed]
19. Médicins sans Frontières. 2012. Undetectable: How Viral Load Monitoring Can Improve HIV Treatment in Developing Countries. MSF, Geneva, Switzerland. http://www.msfaccess.org/our-work/hiv-aids/article/1866.
20. Scott L, Carmona S, Stevens W. 2009. Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J Clin Microbiol 47:34003402.[PubMed]
21. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao JDC. 2009. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol 47:889895.[PubMed]
22. Ruelle J, Jnaoui K, Lefèvre I, Lamarti N, Goubau P. 2009. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 44:297301.[PubMed]
23. Drexler JF, Reber U, Wuttkopf A, Eis-Hübinger AM, Drosten C. 2012. Performance of the novel Qiagen artus QS-RGQ viral load assays compared to that of the Abbott RealTime system with genetically diversified HIV and hepatitis C Virus plasma specimens. J Clin Microbiol 50:21142117.[PubMed]
24. Tyagi S, Kramer FR. 1996. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 14:303308.[PubMed]
25. Xu S, Song A, Nie J, Li X, Wang Y. 2010. Performance of NucliSens HIV-1 EasyQ Version 2.0 compared with six commercially available quantitative nucleic acid assays for detection of HIV-1 in China. Mol Diagn Ther 14:305316.[PubMed]
26. van Deursen P, Oosterlaken T, Andre P, Verhoeven A, Bertens L, Trabaud MA, Ligeon V, de Jong J. 2010. Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS EasyQ HIV-1 v2.0. J Clin Virol 47:120125.[PubMed]

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error